New China Recombinant Insulin Lispro Market Investigation Research Report, 2018-2022 – Industrial IT

0

Global Chinese Recombinant Insulin Lispro Market Growth, Share, Size, Trends and Forecast report provides an in-depth analysis of the China Recombinant Insulin Lispro market including a detailed description of the market size and growth, value, key opportunities in the Chinese Recombinant Insulin Lispro market and describes the factors which are and will drive the growth of the industry taking into account the previous growth models with the forecast period 2022

Get a sample PDF of the report –https://www.marketreportsworld.com/enquiry/request-sample/12855105

Desreportption

According to the report, the rapid development of the Chinese economy over the past 30 years has resulted in changes in people’s lifestyles, for example, reduced exercise and increased calorie intake, this which increases the incidence of diabetes. It is estimated that by the end of 2017, the number of diabetic patients in China had exceeded 100 million. For patients with type 1 diabetes, insulin is the only effective treatment. In addition, 30 to 40% of patients with type 2 diabetes eventually become dependent on insulin.

With the increasing number of diabetic patients, the size of the diabetes medicine market in China is expanding. Third generation insulins such as Insulin Glargine, Insulin Aspart and Insulin Lispro occupy a significant market share.

Recombinant insulin lispro is a new type of insulin analogue which acts faster, lasts less and adapts better to the insulin secretion curve during physiological meals. The preparations Recombinant insulin lispro injection, mixed recombinant human protamine-zinc insulin lispro injection (25R) and mixed recombinant human protamine-zinc insulin lispro injection (50R) can all better control blood sugar and reduce hypoglycemia. Recombinant Lispro insulin was developed by Lilly. Lilly’s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Human Recombinant Lispro Insulin (25R) (trade name: Humalog Mix25) and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50) have been approved by the FDA for the treatment of diabetes between April 1996 and December 1999 and launched in China in 2005, 2010 and 2008 respectively. At the end of 2018, in addition to Lilly’s Humalog, the only recombinant insulin lispro products in China are recombinant insulin lispro injection from domestic manufacturer Gan & Lee Pharmaceuticals and mixed human insulin lispro injection. recombinant protamine and zinc (25R) that have been launched. in 2006 and 2014 respectively.

Recombinant insulin lispro has grown rapidly since entering China, with annual sales value falling from less than CNY 7 million in 2005 to CNY 243 million in 2017, according to the report. Recombinant lispro in the Chinese market are Lilly and Gan. & Lee Pharmaceuticals. In terms of sales, Lilly’s recombinant insulin lispro market share exceeded 98% in 2017, but is slowly declining. Optimistic about the Chinese recombinant insulin lispro market, other national pharmaceutical companies are stepping up imitation of recombinant insulin lispro. For example, in October 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA has approved clinical trials of its recombinant insulin lispro injection, its protamine-zinc mixed recombinant human insulin injection Lispro (25R) and its recombinant human protamine-zinc mixed injection. Insulin Lispro Injection (50R). It is expected that over the next few years, more recombinant insulin lispro products by national pharmaceutical companies will be launched.

As the number of diabetic patients is expected to continue to increase, the Chinese recombinant insulin lispro market will still have some growth potential.

Topics covered:

– Status of diabetes and market overview of anti-diabetic drugs in China

– Recombinant insulin lispro market size in China

– Main manufacturers of recombinant insulin Lispro in China

– Price of recombinant insulin lispro in China

– Main factors affecting the development of the Chinese Recombinant Insulin Lispro Market

– Perspective of the Chinese recombinant insulin lispro market

Inquire Before Purchasing This Report – https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12855105

The China Recombinant Insulin Lispro Market report provides an overview of key market drivers, challenges, opportunities and risks and vendor strategies. The major players are also presented with their market shares in the global Recombinant Insulin Lispro market in China. Overall, this report covers the historical situation, current state and future prospects. Moreover, the global market is segmented on the basis of type, application, offerings, and region. It contains numbers, regions, revenue and offers just like the in-depth calculation of business chain structure, opportunities and industry news analysis. The application part shows the uses of the product.

The China Recombinant Insulin Lispro market report also covers a detailed understanding of the major geographies present in the market along with key segments and sub-segments. The report focuses on the state of regional development, which includes market size, share and volume.

Purchase this report (price 2200 USD for a single user license) – https://www.marketreportsworld.com/purchase/12855105

Detailed Table of Contents of Global Synthesis Gas Market Research Report

Contents
1 Relevant concepts of recombinant insulin lispro
1.1 Indications for recombinant insulin lispro
1.2 Development of recombinant insulin lispro in China
1.3 Government approval of recombinant insulin lispro in China

2 Sales of Recombinant Insulin Lispro in China, 2013-2017
2.1 Sales value of recombinant insulin lispro
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Recombinant insulin lispro sales volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Recombinant Insulin Lispro Sales by Dosage Form, 2013-2017

3 Major Manufacturers Analysis of Recombinant Lispro Insulin in China, 2013-2017
3.1 Major Manufacturers of Recombinant Insulin Lispro Market Share Analysis
3.1.1 Market share by sales value
3.1.2 Market share by sales volume
3.2 Lily
3.2.1 Company profile
3.2.2 Sales of Lilly’s Recombinant Insulin Lispro (Humalog) in China
3.3 Gan & Lee Pharmaceuticals
3.3.1 Company profile
3.3.2 Sales of Recombinant Insulin Lispro (Prandilin) ​​by Gan & Lee Pharmaceuticals in China

4 Price of Recombinant Insulin Lispro in China, 2017-2018
4.1 Lilly (Humalogue)
4.2 Gan & Lee Pharmaceuticals (Prandilin)

5 China Recombinant Insulin Lispro Market Outlook, 2018-2022
5.1 Analysis of factors affecting the development of the Chinese Recombinant Insulin Lispro Market
5.2 Advancement of Generic Recombinant Insulin Lispro in China
5.3 Recombinant Insulin Lispro Market Trend Forecast

Browse the full table of contents at – https://www.marketreportsworld.com/TOC/12855105

About Us: –

World Market Reports is the credible source for getting the market reports that will give you the lead your business needs. The market is changing rapidly with the continued expansion of the industry. The advancement of technology has provided today’s businesses with multifaceted benefits resulting in daily economic changes. Thus, it is very important for a company to understand the patterns of market movements in order to better develop a strategy. An effective strategy gives businesses a head start in planning and an edge over the competition.

CONTACT US

Name: Ajay Plus

E-mail: [email protected]

Call: United States + (1) 424 253 0807 / United Kingdom + (44) 203 239 8187

Other reports here:

Dental CBCT Market Size 2022 Key Global Findings, Industry Demand, Regional Analysis, Major Player Profiles, Future Outlook and Forecast Till 2030

Dental CBCT Market Size 2022 Key Global Findings, Industry Demand, Regional Analysis, Major Player Profiles, Future Outlook and Forecast Till 2030

Dental CBCT Market Size 2022 Key Global Findings, Industry Demand, Regional Analysis, Major Player Profiles, Future Outlook and Forecast Till 2030

Dental CBCT Market Size 2022 Key Global Findings, Industry Demand, Regional Analysis, Major Player Profiles, Future Outlook and Forecast Till 2030

Dental CBCT Market Size 2022 Key Global Findings, Industry Demand, Regional Analysis, Major Player Profiles, Future Outlook and Forecast Till 2030

ICT investment trends in telecommunications or services market share, global manufacturer size, consumption, drivers, major countries, trends, force analysis, revenue, challenges and global forecast to 2026

ICT investment trends in telecommunications or services market share, global manufacturer size, consumption, drivers, major countries, trends, force analysis, revenue, challenges and global forecast to 2026

ICT investment trends in telecommunications or services market share, global manufacturer size, consumption, drivers, major countries, trends, force analysis, revenue, challenges and global forecast to 2026

ICT investment trends in telecommunications or services market share, global manufacturer size, consumption, drivers, major countries, trends, force analysis, revenue, challenges and global forecast to 2026

ICT investment trends in telecommunications or services market share, global manufacturer size, consumption, drivers, major countries, trends, force analysis, revenue, challenges and global forecast to 2026

Share.

Comments are closed.